200 related articles for article (PubMed ID: 34046915)
1. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
Chen X; Cui X; Pognan N; Quinlan M; Kapoor S; Rahmanzadeh G; Giovannini M; Marbury TC
Br J Clin Pharmacol; 2022 Jan; 88(1):91-102. PubMed ID: 34046915
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects.
Cui X; Chen X; Pognan N; Sengupta T; Rahmanzadeh G; Kornberger R; Giovannini M
J Clin Pharmacol; 2023 Feb; 63(2):228-238. PubMed ID: 36087217
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.
Taylor L; Crockett J; Tayo B; Morrison G
J Clin Pharmacol; 2019 Aug; 59(8):1110-1119. PubMed ID: 30921490
[TBL] [Abstract][Full Text] [Related]
4. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
[TBL] [Abstract][Full Text] [Related]
6. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
Grande E; Giovannini M; Marriere E; Pultar P; Quinlan M; Chen X; Rahmanzadeh G; Curigliano G; Cui X
Br J Clin Pharmacol; 2021 Jul; 87(7):2867-2878. PubMed ID: 33300203
[TBL] [Abstract][Full Text] [Related]
7. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.
Chen X; Isambert N; López-López R; Giovannini M; Pognan N; Kapoor S; Quinlan M; You B; Cui X; Rahmanzadeh G; Mau-Sorensen M
Br J Clin Pharmacol; 2023 Mar; 89(3):1046-1055. PubMed ID: 36131603
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
[TBL] [Abstract][Full Text] [Related]
10. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
12. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
[TBL] [Abstract][Full Text] [Related]
13. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Moreno V; Greil R; Yachnin J; Majem M; Wermke M; Arkenau HT; Basque JR; Nidamarthy PK; Kapoor S; Cui X; Giovannini M
Clin Ther; 2021 Jun; 43(6):1092-1111. PubMed ID: 34053700
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?
Phelan M; Anzures-Cabrera J; Carlile DJ; Rowell L; Kuhlmann O; Arold G; Robson R; Bentley D
Clin Pharmacokinet; 2013 Apr; 52(4):255-65. PubMed ID: 23400900
[TBL] [Abstract][Full Text] [Related]
17. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study.
Marbury T; El-Hashimy M; Blumenstein L; Letellier F; Sengupta T; Lorenzo S; Preston RA
J Cancer; 2023; 14(9):1571-1578. PubMed ID: 37325049
[TBL] [Abstract][Full Text] [Related]
19. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]